公开(公告)号：US20190010246A1

公开(公告)日：2019-01-10

申请号：US15996369

申请日：2018-06-01

申请人： Compugen Ltd.

发明人： Spencer Liang ,  Ling Leung ,  Sarah Whelan ,  Maya Kotturi ,  Eran Ophir ,  Arthur Machlenkin ,  Zoya Alteber ,  Meir Azulay ,  Sandeep Kumar ,  Radhika Desai ,  Christopher Chan ,  Kathryn Logronio

IPC分类号： C07K16/30 ,  A61P35/00

摘要： The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.

公开(公告)号：US20230070685A1

公开(公告)日：2023-03-09

申请号：US17544852

申请日：2021-12-07

申请人： Compugen Ltd.

发明人： Spencer Liang ,  Ling Leung ,  Sarah Whelan ,  Maya Kotturi ,  Eran Ophir ,  Arthur Machlenkin ,  Zoya Alteber ,  Meir Azulay ,  Sandeep Kumar ,  Radhika Desai ,  Christopher Chan ,  Kathryn Logronio

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

摘要： The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.

公开(公告)号：US11225523B2

公开(公告)日：2022-01-18

申请号：US15996369

申请日：2018-06-01

申请人： Compugen Ltd.

发明人： Spencer Liang ,  Ling Leung ,  Sarah Whelan ,  Maya Kotturi ,  Eran Ophir ,  Arthur Machlenkin ,  Zoya Alteber ,  Meir Azulay ,  Sandeep Kumar ,  Radhika Desai ,  Christopher Chan ,  Kathryn Logronio

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61P35/00 ,  A61K38/17 ,  C07K16/24 ,  C07K16/42 ,  G01N33/574

摘要： The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.